losartan has been researched along with Epidermolysis Bullosa, Junctional in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Epidermolysis Bullosa, Junctional: Form of epidermolysis bullosa having onset at birth or during the neonatal period and transmitted through autosomal recessive inheritance. It is characterized by generalized blister formation, extensive denudation, and separation and cleavage of the basal cell plasma membranes from the basement membrane.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tartaglia, G | 1 |
| Park, PH | 1 |
| Alexander, MH | 1 |
| Nyström, A | 1 |
| Rosenbloom, J | 1 |
| South, AP | 1 |
1 other study available for losartan and Epidermolysis Bullosa, Junctional
| Article | Year |
|---|---|
Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa.
Topics: Animals; Epidermis; Epidermolysis Bullosa, Junctional; Losartan; Mice; Skin | 2023 |